# Rainier Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rainier-therapeutics

- Industry: Biotechnology
- Headquarters: San Leandro, US
- Website: www.bioclintherapeutics.com
- Total disclosed funding: $79M
- Latest round: Series B (May 9, 2018)
- Investors on record: 7

## About

Rainier Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative treatments for chronic medical conditions, leveraging advanced biotechnology to enhance patient care.Rainier Therapeutics, Inc. operates in San Leandro, US, and was founded in 2010. The company specializes in creating biopharmaceutical products aimed at unmet medical needs. In July 2021, Fusion Pharmaceuticals Inc. acquired Rainier Therapeutics, Inc. for undisclosed financial terms. The company has completed a total of 9 deals, with its latest funding round in 2021 amounting to USD 10.00 mn, which matches the total amount raised of USD 10.00 mn.BioClin Therapeutics specializes in developing innovative biopharmaceutical products aimed at addressing unmet medical needs in the therapeutic arena. Their core offerings include a range of biologic treatments tailored for various chronic conditions, focusing on enhancing patient outcomes through targeted therapies. These products leverage advanced biotechnology methodologies to facilitate precise action within the human body, ultimately improving disease management. With a clientele that spans hospitals, healthcare providers, and research institutions, the company aims to cater to both domestic and international markets, specifically targeting regions such as North America and Europe. Their end-users include healthcare professionals and patients seeking effective solutions for complex health challenges.The revenue structure of BioClin Therapeutics is primarily driven by direct sales to healthcare institutions and partnerships with pharmaceutical distributors. Transactions typically occur through a B2B model, where healthcare facilities and research organizations acquire the company's products as part of their treatment protocols. Flagship products may be offered under subscription models or bulk procurement agreements, facilitating consistent revenue streams. While specific pricing plans for each product are not disclosed, the company’s revenue results from these arrangements, ensuring a steady flow of capital from established networks within the healthcare industry.Rainier Therapeutics plans to utilize its recent funding of USD 10.00 mn to support the development of new biopharmaceutical products aimed at chronic conditions. The company is looking to expand its market presence in North America and Europe by 2024, with strategic initiatives to enhance its distribution networks. Recent acquisitions and partnerships will play a crucial role in facilitating entry into these markets.

## Funding rounds

- Series B, May 9, 2018, $30M — Sofinnova Investments, HealthCap, EQT Life Sciences, Ysios Capital Partners, Inkef, Sectoral Asset Management
- Series B, Apr 27, 2018, $30M — Sofinnova Investments, HealthCap, EQT Life Sciences, Tekla Capital Management, Ysios Capital Partners
- Series A, Jan 21, 2016, $13M — HealthCap, EQT Life Sciences, Tekla Capital Management
- Series A, Apr 2, 2014, $6M — HealthCap

## Investors

- HealthCap — Series A, Series B
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series A, Series B
- Tekla Capital Management (https://capitalatlas.ai/funds/tekla-capital-management) — Series A, Series B
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series B
- Ysios Capital Partners (https://capitalatlas.ai/funds/ysios-capital-partners) — Series B
- Inkef (https://capitalatlas.ai/funds/inkef) — Series B
- Sectoral Asset Management (https://capitalatlas.ai/funds/sectoral-asset-management) — Series B